Male osteoporosis

Endocrinol Metab Clin North Am. 2012 Sep;41(3):629-41. doi: 10.1016/j.ecl.2012.05.001. Epub 2012 Jun 17.

Abstract

Osteoporosis is now recognized as a major threat to health in aging men. Morbidity and mortality, particularly following hip fracture, are substantial. Although trabecular bone loss starts in early adulthood, loss of cortical bone only seems to occur from midlife onwards. Declining bioavailable estradiol levels plays an integral role in male age-associated bone loss. Both pharmacologic and supportive care interventions are important for optimal care in men at an increased fracture risk.

Publication types

  • Review

MeSH terms

  • Aging*
  • Bone Density / drug effects
  • Bone Density Conservation Agents / therapeutic use
  • Bone and Bones / drug effects
  • Hormone Replacement Therapy
  • Humans
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporosis / epidemiology
  • Osteoporosis / etiology*
  • Osteoporosis / physiopathology
  • Osteoporotic Fractures / etiology
  • Osteoporotic Fractures / prevention & control
  • RANK Ligand / antagonists & inhibitors
  • Risk Factors

Substances

  • Bone Density Conservation Agents
  • RANK Ligand